跳至主要内容
临床试验/NCT05700773
NCT05700773招募中不适用

Assessing the Relationship Between Myonectin Concentration and the Course of Hospitalization and the 30-day Risk of Cardiac Endpoints in Patients With the First Incident of ST-segment Elevation Mycardial Infarction Treated With Primary PCI

Michał Jaśkiewicz1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
30-day mortality

研究概览

简要总结

The aim of this study is to test the potentially protective role of myonectin in patients with a first episode of ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI).

The main questions which are assumed to be answered after study completion:

  1. Does higher myonectin concentration influence the in-hospital and 30-day course of the first ST-elevation MI in patients treated with primary coronary angioplasty
  2. Is there a relationship between the serum myonectin concentration, related to patient's nutritional status and physical activity with the patient's physical activity declared as usually before the coronary event occurrence, the cardiac biomarkers level, and myocardial and skeletal muscle mass determined in order to objectify the relationship of physical activity before the infarction with 30-day and one-year mortality, and the other primary and secondary outcomes measured at 12-month visit, e.g. the extent of myocardial infarction,
  3. Is there a relationship between the baseline concentration of myonectin and troponin with the control of atherosclerosis risk factors, declared physical activity and parameters of body composition, outcome of treadmill exercise test, values of echocardiographic parameters and myonectin concentration 12 months after a cardiovascular incident

详细描述

Myonectin or Complement C1q Tumor Necrosis Factor - Related Protein 15 (CTRP15) is a cytokine secreted by skeletal muscle. The participation of myonectin in the regulation of lipid homeostasis in the liver and adipose tissue has been proven. The concentration of myonectin depends on the nutritional status of the organism, it decreases during fasting and increases after feeding. In studies on mice, a protective effect of high concentrations of myonectin on the course of myocardial infarction was observed. The effect of regular physical exercise on the concentration of myonectin in the serum was also demonstrated. Abnormal function of myokines, including myonectin, has also been linked to sarcopenia, which significantly negatively affects the prognosis of patients with heart failure.

Potentially protective properties of myonectin in the case of ischemia-reperfusion injury in the course of myocardial infarction have not been studied in humans so far.

Myonectin may become a potentially useful prognostic indicator of the severity of myocardial infarction. It may also potentially become a target for a new cardioprotective therapy in patients with acute myocardial ischaemia.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • symptoms of acute coronary syndrome
  • acute ST segment elevation in two or more leads in ECG
  • primary PCI

排除标准

  • pregnancy
  • patients unconscious, with altered consciousness or not able to cooperate
  • cardiogenic shock
  • significant physical effort within 24 hours before onset of MI
  • active infection at admission, intramuscular injection
  • myocardial infarction in patient's medical history
  • heart failure New York Heart Association (NYHA) class III - IV in patient's medical history
  • renal failure (chronic kidney disease, CKD) with glomerular filtration rate (GFR) < 30ml/min
  • history of malignant neoplasms in the last 5 years
  • patients incapacitated, active soldiers, imprisoned or related with investigators

结局指标

主要结局

30-day mortality

时间窗: 30 days

All-cause mortality

12-month mortality

时间窗: 12 months

All-cause mortality

Stroke

时间窗: 12 months

Any stroke or transient ischaemic attack (TIA) during follow-up

Myocardial infarction

时间窗: 12 months

Any myocardial infarction during follow-up

Bleeding

时间窗: 12 months

Any registered clinically significant bleeding

次要结局

  • Cardiac Troponin T(up to 7 days)
  • Length of hospitalization(30 days)
  • Myonectin serum concentration(up to 7 days and 12 months)
  • Left Ventricular Internal Dimension at End of Diastole (LVIDd)(up to 7 days and 12 months)
  • Left Ventricular Ejection Fraction(up to 7 days and 12 months)

研究者

发起方
Michał Jaśkiewicz
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Michał Jaśkiewicz

Principal Investigator; Consultant in Interventional Cardiology

Wojewodzki Szpital Zespolony w Elblagu

研究点 (1)

Loading locations...

相似试验